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Aims We have investigated Ca
2+ signalling generated by aldosterone-induced T-type current (ICaT), the effects of ICaT in
neonatal cardiomyocytes, and a putative role for ICaT in cardiomyocytes during cardiac pathology induced by stenosis
in an adult rat.
Methods
and results
Neonatal rat cardiomyocytes treated with aldosterone showed an increase in ICaT density, principally due to the
upregulation of the T-type channel Cav3.1 (by 80%). Aldosterone activated cAMP-response element-binding
protein (CREB), and this activation was enhanced by blocking ICaT or by inhibiting protein phosphatase 2A (PP2A)
activity. Aldosterone induced PP2A activity, an induction that was prevented upon ICaT blockade. ICaT exerted a nega-
tive feedback regulation on the transcription of the Cav3.1 gene, and the activation of PP2A by ICaT led to increased
levels of the pro-apoptotic markers caspase 9 and Bcl-xS and decreased levels of the anti-apoptotic marker Bcl-2.
These ﬁndings were corroborated by ﬂow cytometry analysis for apoptosis and necrosis. Similarly, in a rat model
of cardiac disease, ICaT re-emergence was associated with a decrease in CREB activation and was correlated with
increases in caspase 9 and Bcl-xS and a decrease in Bcl-2 levels.
Conclusion Our ﬁndings establish PP2A/CREB as targets of ICaT-generated Ca
2+ signalling and identify an important role for ICaT
in cardiomyocyte cell death.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
Keywords Apoptosis † Cav3.1 channel † Gene expression † Glucocorticoid receptor † Protein phosphatase
1. Introduction
Ca
2+ entry through T-type channels was reported to have two main
roles, one related to cell excitability and the other to the stimulation
of a range of Ca
2+-dependent biological events.
1–3 In ventricular car-
diomyocytes, both Cav3.1 and Cav3.2 channel subunits are respon-
sible for ICaT, and the pattern of expression of these channels varies
with the stage of heart development.
4–6 The reappearance of ICaT
in adult cardiomyocytes was reported, in association with several
aetiologies of ventricular hypertrophy.
3 However, little is known
about the mechanism involved in the regulation of T-type channel
expression, and the ICaT-dependent Ca
2+ signalling pathway remains
to be explored.
It has repeatedly been demonstrated that Cav3.1 and Cav3.2 are
regulated differently and have different cellular functions. Consistent
with this observation, mice lacking Cav3.1 have a cardiac phenotype
different from that of mice lacking Cav3.2 and, similarly, mice overex-
pressing the Cav3.1 gene have a response to hypertrophic stimuli very
different from that of mice overexpressing the Cav3.2 gene.
7,8
However, the role of ICaT in the development of cardiac hypertrophy
remains a matter of debate, as does the identity of the channel subunit
involved. Indeed, Chiang et al.
7 reported that cardiac hypertrophy was
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whereas Nakayama et al.
8 described an anti-hypertrophic role for
Cav3.1. Our previous work with an in vivo model provided evidence
that the pathological re-expression of Cav3.1 and, to a lesser
extent, Cav3.2 channels was independent of cardiac hypertrophy per
se, and we suggested that ICaT might be associated with end-stage
organ damage during cardiac disease.
9 Consistent with this hypothesis,
the use of mibefradil, an ICaT antagonist, was shown to improve survi-
val in a rat model of chronic heart failure such as sudden death and
ﬁbrillation, suggesting that ICaT blockade might have a beneﬁcial
impact on cardiac diseases.
10,11
Aldosterone is known to be involved in the development of cardiac
hypertrophy and failure, and was described as participating in electro-
physiological remodelling in ventricular myocytes, increasing both
L-type Ca
2+ current (ICaL) and ICaT.
12,13 In this study, we used aldos-
terone to investigate the mechanisms involved in channel gene
expression, to identify the signalling pathways triggered by ICaT-
generated Ca
2+ inﬂux, and to determine the cellular impact of ICaT-
generated Ca
2+ signalling in cardiomyocytes. We found that
aldosterone-dependent ICaT-generated Ca
2+ signalling induced nega-
tive feedback on cAMP-response element-binding protein (CREB)
via protein phosphatase 2A (PP2A). Through its targeting of PP2A,
ICaT increased pro-apoptotic markers and cell death. These ﬁndings
implicate ICaT in the regulation of CREB-dependent gene expression
and ICaT/PP2A/CREB signalling in promoting apoptosis.
2. Methods
2.1 Animals and culture conditions
Animals were cared for and used in accordance with the European con-
vention for the protection of vertebrates used for experimental purposes,
and institutional guidelines no. 86/609/CEE 24 November 1986 and con-
forms to the Guide for the Care and Use of Laboratory Animals published
by the US National Institutes of Health (NIH Publication no. 85-23,
revised 1996). Primary cultures of ventricular myocytes were each pre-
pared from hearts of 10 1-day-old male Wistar rats (Charles Rivers,
France) as described previously.
9 Following tissue digestion, cells were
plated (low density, 1 h at 378C) in normal growth medium to isolate car-
diomyocytes from adherent cells. Non-adherent cells were collected,
plated on new dishes, and maintained in serum-free DMEM supplemented
with medium 199 (4:1) and 1 mM cytosine b-D-arabinofuranoside (Sigma),
to prevent proliferation of residual non-myocytes. Cells were exposed to
aldosterone or pre-treated with antagonists or inhibitors prior to addition
of aldosterone. The antagonists or inhibitors used were RU 38486 spiro-
nolactone, mibefradil, ﬂunarizine, ﬂuoxetine, or nifedipine all from Sigma,
FK506, or okadaic acid (OA) from Alexis Biochemicals (San Diego, CA,
USA) and dexamethasone from Sigma.
The hypertrophic model was described elsewhere.
9 Brieﬂy, adult male
Wistar rats were subjected to abdominal aortic stenosis for 6 (AS6) or 12
weeks (AS12) and controls were age-matched sham-operated rats (Ctl6
and Ctl12). The left ventricles were isolated, rapidly frozen, and stored
at 2808C.
2.2 Electrophysiological recordings
Ca
2+ currents were recorded by whole-cell patch-clamp technique, at
room temperature (22–248C). The ﬁre-polished pipettes used had a
resistance of 1–3 MV when ﬁlled with pipette solution: 10 mM CsCl,
120 mM Cs-aspartate, 3 mM MgCl2, 10 mM HEPES, 15 mM EGTA,
1.8 mM CaCl2, 10 mM glucose, 3.6 mM creatine phosphate, 5 mM
MgATP, 0.2 mM Tris-GTP, pH 7.2, adjusted with CsOH. Ca
2+ currents
were recorded in an external solution containing: 135 mM TEA-Cl,
1 mM MgCl2, 10 mM CaCl2, 10 mM HEPES, 10 mM glucose, 3 mM 4–
aminopyridine, 20 mM CsCl, 0.03 mM tetrodotoxin, pH 7.4, adjusted
with CsOH. Additional details of data recording were reported
elsewhere.
5
2.3 Transfection and luciferase assay
The 3 kb region upstream from cacna1g was isolated from Wistar rat
genomic library (l DASH II, Stratagene) and inserted into the luciferase
reporter pGL3-basic vector (Promega, Madison, WI, USA) as described
previously.
14 The resulting plasmid was used to generate chimeric pGL
promoter/luciferase constructs (pGL4100–pGL4600). The GRE1
mutant (853 bp upstream from the translation start site) resulted from
a point mutation generated in pGL4400 by PCR with 5′TGGAAGG
GCGTCC(T)A(C)TGGA3′ used as the primer. Neonatal myocytes
were cotransfected using luciferase construct and pSVbgal (Promega)
with FuGENE 6 (Roche, Indianapolis, NI, USA). Luciferase and
b-galactosidase activities were determined in a related reporter assay
system (Promega). All experiments were performed on at least three cul-
tures set up in triplicate.
2.4 RNA isolation and mRNA quantiﬁcation
Total RNA samples were prepared from ventricular tissues using Trizol
(Invitrogen). The Cav3.1, Cav3.2, cyclophylin primers, and quantitative
RT–PCR procedures have been described elsewhere.
5,15 Brieﬂy, quanti-
tative RT–PCR was performed with a normalized RNA aliquot (1 mg)
and a known amount of cRNA internal control (2.5 × 10
6 molecules).
The internal control differed from the target counterpart by only one
restriction site. PCR was performed with a trace amount of
32P-labelled
5′ primer. The number of copies per micrograms of total RNA was calcu-
lated using the following equation: [Internal control weight/(size in
nucleotides × 330)] × 6.02 × 10
23, and from the relationship [molecules
cRNA control/cpm cRNA control] × cpm target ¼ target molecules per
normalized RNA aliquot.
2.5 Protein extraction and western blot
analysis and phosphatase activity assay
The preparation of cytosolic, nuclear, and total extracts were described
elsewhere.
14 Antibodies were glucocorticoid receptor (GR), Bcl-xL
Bcl-xS, Bcl-2 (Santa Cruz Biotechnology, CA, USA), total CREB,
Ser-133-phosphorylated CREB (pCREB), caspase 9 (Cell Signaling Tech-
nology, MA, USA), which detects the pro-caspase 9 as well as the
cleaved fragment of caspase 9, catalytic subunit of PP1 (Santa Cruz Bio-
technology), PP2AC, and PP2B (Cell Signaling Technology). Actin (Santa
Cruz) was used for normalization. Protein bands were visualized with
the Lumi-light
plus blotting Kit (Roche) and analysed with Gene Tools
from Syngen (Cambridge, UK). The activity of PP2A was measured with
the Ser/Thr phosphatase assay system (Promega). Phosphatase activity
was calculated as the rate of Pi release from pre-phosphorylated
peptide and normalized with respect to basal levels (sample without
phosphopeptide).
2.6 Flow cytometry
For each treatment, cells were collected after digestion with trypsin.
Samples from each cell suspension were stained with ﬂuorescein isothio-
cyanate (FITC)-conjugated annexin V; propidium iodide (PI) exclusion
assay (PI-Pharmingen) was carried out according to the manufacturer’s
protocol. For each sample, 30 000 cells were analysed on an FACSCalibur
machine, with CELLQuest software (Becton Dickinson, Franklin Lakes, NJ,
USA). Counts are expressed as a percentage of the total number of cells
counted.
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Data are expressed as means+SEM (n ≥ 3). The statistical signiﬁcance of
differences between groups was estimated by one-way ANOVA, followed
by Dunnett’s test or two-way ANOVA, followed by Bonferroni’s test.
Differences were considered signiﬁcant if P , 0.05.
3. Results
3.1 Aldosterone increases Cav3.1-related
current
Cultures of ventricular myocytes treated with aldosterone for 48 h
displayed an increase in ICaT current density (5.7+0.5 pA/pF n ¼
15 vs. 3.6+0.3 pA/pF n ¼ 8 in the control, P , 0.01; Figure 1A and
B) that was not associated with changes in activation or in steady-state
inactivation parameters (Figure 1C). The nature of the Cav3.X-related
current induced by aldosterone was determined on the basis of the
Ni
2+ sensitivity of ICaT (Figure 1D). The Ni
2+ dose–response in
control conditions indicated that ICaT was blocked in the monophasic
mode, with an IC50 of 300 mM, whereas, in aldosterone-treated myo-
cytes, ICaT was blocked in the biphasic mode, with IC50 values of 1.5
and 300 mM( Figure 1D), corresponding to the sensitivities described
for Cav3.2- and Cav3.1-related currents, respectively.
16,17 The relative
contributions of these currents were assessed from the Ni
2+ dose–
response relationship, and we found that Cav3.2 and Cav3.1 contrib-
uted 20 and 80% of the total current, respectively. These relative
contributions of functional Cav3.X channels correspond to obser-
vations reported in pathological conditions.
9
3.2 Aldosterone increases transcription of
the Cav3.1 gene by activating the GR
Quantitative RT–PCR showed that Cav3.1 and Cav3.2 mRNA levels
were higher (by factors of 2.4 and 1.4, respectively) in aldosterone-
treated cells than in control cells (Figure 2A). These results contrast
with those of Laleve ´e et al.
13 who found that aldosterone-induced
ICaT was associated with an increase in the amount of Cav3.2
mRNA (up to 410%) and a non-signiﬁcant increase in the Cav3.1
mRNA level. This discrepancy is probably due to the use of an inap-
propriate normalization marker, cyclophilin, which is repressed in
aldosterone-treated cells, and the use of primers that do not recog-
nize the relevant isoform (data shown and discussed in Supplementary
material online, Figure S1). Thereafter, we have focused our study on
the regulation of Cav3.1 gene expression.
The amount of Cav3.1 mRNA increased in aldosterone-treated
cells, reaching a plateau 9 h after the beginning of treatment
(Figure 2B). Cycloheximide treatment did not prevent
aldosterone-induced increases in mRNA levels during the ﬁrst hour
(Supplementary material online, Figure S2), suggesting that aldosterone
activated pre-existing regulatory factors. However, protein synthesis
was required for a sustained effect of aldosterone, since the Cav3.1
mRNA amount gradually declined after the ﬁrst hour of aldosterone
plus cycloheximide treatment. The effect of the pre-existing transcrip-
tional factor was no longer visible after 9 h of treatment.
We further assessed cacna1g regulation by investigating promoter
activitythroughunidirectionaldeletionsandpointmutations.Aldoster-
one treatment induced an increase in promoter activity, which was
maximal for sequences up to 1.5 kb long(pGL4400) (Figure2C). Aldos-
terone had a dose-dependent effect on Cav3.1 upregulation, and we
foundthatwhencomparedwithcontrol,1 mMinducedan87%increase
of pGL4400 activity and 0.1 mM only 20% increase of pGL4400 activity
(Supplementary material online, Figure S3).
Treatment with the GR antagonist RU 38486 almost completely
turned off the transcription of pGL4400 (and pGL4600, data not
shown) in both aldosterone-treated and untreated cells (Figure 2D).
In contrast, the mineralocorticoid receptor (MR) antagonist spirono-
lactone simply decreased the level of transcription. Several putative
glucocorticoid response elements (GREs) are present in pGL4400.
14
Mutations in GRE1 abolished aldosterone-induced transcription of
the Cav3.1 gene, cacna1g (Figure 2E), but did not alter basal levels
of transcription or the levels of transcription induced by a synthetic
glucocorticoid analogue, dexamethasone. Consistent with these ﬁnd-
ings, the rapid (10 min) translocation of GR from the cytosol to the
nuclear compartment (Figure 2F) was observed in aldosterone-treated
cells, supporting the role of GR in the genomic response of aldoster-
one. After 2 h of incubation with aldosterone, the amount in cytosolic
GR returned to control levels, probably due to de novo GR synthesis.
These ﬁndings are consistent with the involvement of pre-existing
regulatory factors and the need for de novo synthesis for sustained
increases in mRNA levels.
3.3 ICaT modulates cacna1g expression
and CREB activation
To test the hypothesis that ICaT is likely to play a role in the control of
gene expression, we investigated the effect of the ICaT blockers
Figure 1 AldosteroneincreasesprincipallyCav3.1-generatedT-type
calcium current. (A) Typical recordings are shown forcontrol(Ctl) and
aldosterone treatment (Aldo, 1 mM). (B) ICaT density–voltage relation-
ships in Ctl (n ¼ 8) and Aldo (n ¼ 15). (C) Voltage-dependent acti-
vation (squares) and steady-state inactivation (circles) curves.
Activation: V0.5 ¼ 227.0+2.6 mV, k ¼ 5.8+0.5 mV for Ctl (n ¼ 6);
V0.5 ¼ 231.4+0.4 mV, k ¼ 4.8+0.1 mV for Aldo (n ¼ 11). Inacti-
vation V0.5 ¼ 263.7+1.5 mV, k ¼ 24.3+0.2 mV for Ctl (n ¼ 6);
V0.5 ¼ 260.4+0.5 mV, k ¼ 24.7+0.1 mV for Aldo (n ¼ 8). (D)
Dose–response curves for Ni
2+ on ICaT recorded from a holding
potential of 2100 mV to a test pulse of 220 mV. n ¼ 5–10 cells for
each Ni
2+ concentration. For Ctl, the IC50 is 300 mM. For aldosterone,
two IC50 values were determined: 1.5 and 300 mM. *P , 0.05 vs. Ctl.
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18–20 on cacna1g expression
(Figure 3A). During the exponential phase of mRNA accumulation
(until 6 h—Figure 2B), Ca
2+ current blockers had no effect on the
amount of Cav3.1 mRNA (Figure 3A). However, during the plateau
phase (9 h), Cav3.1 mRNA levels were higher with aldosterone plus
mibefradil (AM) or ﬂunarizine (AFluna) [or ﬂuoxetine (AFluo), data
not shown] than with aldosterone alone. Blocking ICaL with nifedipine
had no additional effect. The aldosterone-induced increase in ICaT
density triggered negative feedback control over cacna1g expression
that was conﬁrmed by the stronger promoter activity observed in
pGL4400-transfected cells exposed to AM than in transfected cells
exposed to aldosterone alone (Figure 3B). We then focused on the
transcription factors regulated by ICaT-generated Ca
2+ inﬂux. As GR
can interact with the CREB,
21 we investigated the effect of ICaT block-
ade on GR translocation and CREB activation. GR translocation was
unchanged in cells exposed to AM or AFluna (Supplementary material
online, Figure S4). Aldosterone induced a rapid increase in Ser133-
phosphorylated CREB protein levels in the nucleus (Figure 3C), and
aldosterone-induced CREB activation was doubled by ICaT blockade
(Figure 3D). The level of total CREB remained stable within these
culture conditions (data not shown).
Finally, we used a rat model of abdominal aortic stenosis to
examine the possible relationship between ICaT and CREB phos-
phorylation in pathological conditions. We have previously shown
that ICaT only re-emerges after long-term stenosis, well after the
establishment of compensated hypertrophy. Indeed, ICaT was absent
6 weeks after the induction of stenosis and re-emerged after 12
weeks of stenosis.
9 We show here that CREB phosphorylation
levels were increased in the 6-week stenosis group compared with
the sham-operated group, whereas CREB phosphorylation was
almost abolished in the 12-week stenosis group (Figure 3E). Decrease
in CREB phosphorylation was prevented in conditions in which ICaT
re-expression was diminished (Supplementary material online,
Figure S5).
3.4 ICaT modulates CREB activation
via PP2A
Many signalling pathways are thought to control CREB phosphoryl-
ation status, depending on cell and physiopathological status.
22 We
investigated the involvement of the serine threonine phosphatases
1, 2A, and 2B (PP1, PP2A, and PP2B), to identify the protein phospha-
tases modulating CREB activation during aldosterone treatment
(Figure 4). Cells were treated with the PP2B (calcineurin) inhibitor
FK506 (1 mM) or with the PP2A inhibitor OA (5 nM) (Figure 4A).
OA treatment increased phosphorylated CREB levels in control and
aldosterone-treated cells. In contrast, FK506 treatment prevented
the aldosterone-induced increase in phosphorylated CREB levels
but had no effect on these levels in control cells. Neither OA nor
FK506 affected total CREB levels (data not shown).
PP2A and PP1 activities were determined in vitro for cardiomyocyte
lysates and could be separated on the basis of sensitivity to OA con-
centration (Figure 4B). In aldosterone-treated cells, total PP2A–PP1
activity was twice that in control cells, mostly due to an increase in
PP2A activity. Indeed, 80+5% of phosphatase activity was abolished
by PP2A blockade (OA—12 nM). The aldosterone-induced increase
in PP2A–PP1 activity was prevented by the ICaT blockers. The small
contribution of PP1 in aldosterone-treated cells was conﬁrmed
using an inhibitor of PP1, and its activation shown to depend on ICaT-
generated Ca
2+ signalling (Figure 4B, bottom panel). Finally, we were
unable to detect a signiﬁcant difference in the amounts of the catalytic
subunits of PP1, PP2A, and PP2B, under the different culture
Figure 2 Aldosterone increases Cav3.1 expression by activating GRs. (A) Quantitative RT–PCR of Cav3 subunits in cells treated by 1 mM aldos-
terone for 24 h, n ¼ 5 for each point. (B) Increase in Cav3.1 mRNA levels over time, n ¼ 4 performed in duplicate for each point. (C) cacna1g pro-
moter activity. AgeI (A), BglII (B), HindIII (H), StuI (St), XbaI (Xb) and XhoI (X). Mean relative luciferase activity (RLA) units+SE. (D) Effect of
spironolactone (spi, 10 mM) and RU 38486 (RU, 10 mM) on pGL4400-transfected cells. n ¼ 3 performed in triplicate. (E) Identiﬁcation of the func-
tional GRE in cacna1g promoter. Cells were transfected with either wild-type pGL4400 (WT) or mutated pGL4400-GRE1 (mGRE1) and exposed to
1 mM aldosterone or 10 mM dexamethasone (Dex), n ¼ 3 performed in triplicate. (F) Nuclear translocation of GRs in aldosterone-treated cells.
Western blots were performed with cytosolic (S1, n ¼ 3) and nuclear extracts (NE, n ¼ 3) performed in triplicate. *P , 0.05, ns vs. Ctl.
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fore, aldosterone-induced ICaT upregulates the level of phosphatase
activity through post-transcriptional regulation rather than changes
in phosphatase gene expression.
3.5 ICaT modulates cell-death markers
via PP2A
An increase in PP2A activity was associated with cell death.
23 We
investigated whether ICaT-induced PP2A activity might be involved
in cardiomyocyte death (Figure 5). An increase in activated caspase
9 levels occurred only 9 h after the start of the treatment
(Figure 5A) in parallel with a time-dependent effect of ICaT blockade
(Figure 3A). At this time point, treatment with OA prevented the
aldosterone-induced caspase 9 activation. Aldosterone also induced
a switch between the Bcl-xL and Bcl-xS variants, which was prevented
by the use of OA or OA plus mibefradil (Figure 5B). These results indi-
cated that the timing of PP2A activation was related to an increase in
ICaT-generated Ca
2+ inﬂux. The relationship between ICaT and the
activation of pro-apoptotic markers was conﬁrmed in cells treated
for 24 h with aldosterone, in which the increase in caspase 9 and
Figure 3 ICaTblockadeupregulatescacna1gexpressionandincreases
pCREB protein levels. (A)E f f e c to fICaT blockade on the increase in
Cav3.1mRNAlevelsovertime.Cellswereculturedwith1 mMmibefr a-
dil (CM),mibefradil plus1 mM aldosterone (AM),mibefradil plusaldos-
terone and 5 mM nifedipine (AMN) or with aldosterone, and 10 mM
ﬂunarizine (AFluna), for the times indicated. n ¼ 4 for each condition,
*P , 0.05 vs. aldosterone. (B)E f f e c to f1mM mibefradil on pGL4400
activity,n ¼ 3performedintriplicate.(C)Nucleartranslocationofphos-
phorylatedCREB.Westernblotswereperformedwithnuclearextracts
from cells subjected to short-term aldosterone treatment. n ¼ 4p e r -
formed in duplicate. (D)E f f e c to fICaT blockade on CREB activation.
Western blots were performed with total protein extracts from cells
treated for 24 h. n ¼ 3 performed in duplicate. (E) Phosphorylated
CREB levels in the pathological model. Western blots were performed
withtotalproteinextractsfromleftventriclesof6(n ¼ 4)or12(n ¼ 6)
weeks stenosed rats (AS6 and AS12) paired with sham-operated rats
(Ctl6, n ¼ 4 and Ctl12, n ¼ 5). *P , 0.05.
Figure 4 ICaT blockade decreases PP2A-induced CREB depho-
sphorylation. (A) Effect of PP2A and PP2B on CREB phosphorylation.
Total proteins were extracted from cells exposed for 24 h to 1 mM
FK506 (FK) or 5 nM okadaic acid (OA). n ¼ 3 performed in duplicate.
(B) Aldosterone increases PP2A–PP1 activities via ICaT signalling. Total
PP2A and PP1 activities were quantiﬁed in cells treated for 24 h with
1 mM aldosterone and 1 mMm i b e f r a d i lo r5 mMﬂ u o x e t i n e( A M ,
AFluo) or ICaT and ICaL blockers (AMN); 12 nM OA blocked PP2A
activity and 5 mM OA blocked PP2A and PP1 activities. Protein phos-
phatase inhibitor-2 (I-P1) blocked PP1 activity. PhosPep ¼ 0.1 mM
phosphopeptide alone. n ¼ 3 performed in triplicate. *P , 0.05.
ICaT activates PP2A and cardiomyocyte death 109Bcl-xS levels and the decrease in Bcl-2 levels were reversed by treat-
ment with mibefradil or ﬂuoxetine (Figure 5C).
Finally, using a rat model of cardiac hypertrophy, we have shown
in long-term stenosis (12 weeks treatment—AS12) that the levels
of caspase 9 and Bcl-xS markedly increased, whereas the reciprocal
effect was seen on Bcl-2, when compared with the sham group
(Ctl12) (Figure 5D). Only the levels of Bcl-xS increased during
hypertrophy (6 weeks treatment—AS6 vs. Ctl6) or ageing (Ctl12
vs. Ctl6).
3.6 Aldosterone-induced ICaT contributes
to myocyte apoptosis and necrosis
Apoptosis was quantiﬁed by FACS analysis after staining with annexin
V-FITC and PI. As previously reported,
24 aldosterone induced cardio-
myocyte apoptosis in cells treated for 24 h, as shown by ﬂow cytome-
try (annexin V-stained cells, Q2 + Q4) (Figure 6A). However, longer
periods of exposure to aldosterone (48 h) increased the number of
necrotic PI-stained cells (Q1) (P , 0.05 vs. Q1 aldosterone 24 h),
whereas no signiﬁcant difference was found in the number of
annexin V—or annexin V + PI-stained cells (Q2 + Q4) between 24
and 48 h of aldosterone exposure. Treatment with AM decreased
the effect of aldosterone on cell death, as shown by smaller
numbers of necrotic cells (P , 0.05, Q1 AM vs. Q1 aldosterone
48 h) and apoptotic cells (P , 0.05, Q2 + Q4 AM vs. Q2 + Q4 aldos-
terone 48 h). Treatment with AFluo also reduced the number of
necrotic cells (P , 0.05, Q1 AFluo vs. Q1 aldosterone 48 h) but did
not signiﬁcantly reduce the number of annexin V-stained cells
(Q2 + Q4) vs. (Q2 + Q4) aldosterone 48 h. The use of nifedipine
in addition to aldosterone plus mibefradil (AMN) enhanced the
effect of AM reducing further the number of PI-stained cells (P ,
0.05, Q1 AMN vs. Q1 AM and Q1 AMN vs. Q1 aldosterone 48 h).
In conclusion, the use of mibefradil with or without nifedipine
Figure 5 Aldosterone induces pro-apoptotic markers via PP2A.
(A) Aldosterone-induced time-dependent activation of caspase
9. Cells exposed to 1 mM aldosterone were treated with 5 nM
OA (A OA) for the time periods indicated. n ¼ 3 performed in dupli-
cate. (B) Aldosterone-induced increase in the Bcl-xS variant via
PP2A. Cells were exposed for 9 h to 1 mM aldosterone, together
with 5 nM OA (A OA) or 1 mM mibefradil + 5 nM OA (AM OA).
n ¼ 3 performed in duplicate. (C) Effect of ICaT blockers on the
aldosterone-induced increase in apoptotic markers in cells treated
for 24 h. n ¼ 3 performed in duplicate. (D) Expression of apoptotic
markers in the pathological model. Proteins were extracted from left
ventricles of 6- and 12-week stenosed rats paired with control. Ctl6
and AS6 n ¼ 4, Ctl12 n ¼ 5 and AS12 n ¼ 6. *P , 0.05.
Figure 6 ICaT blockade reduces aldosterone-induced myocyte
apoptosis and necrosis. (A) Representative graphs from ﬂow cytome-
try analysis. Cells were treated for the indicated periods before
annexin V-FITC/PI double staining. Q1 ¼ annexin V-negative/
PI-positive, Q2 ¼ annexin V-positive/PI-positive, Q3 ¼ annexin
V-negative/PI-negative and Q4 ¼ annexin V-positive/PI-negative.
Annexin V and PI labelled pro-apoptotic and necrotic cells, respect-
ively. (B) Cell viability from annexin V-negative/PI-negative stained
cells. Clt and Aldo 48 h n ¼ 6, Aldo 24 h and AMN n ¼ 4, AM
and AFluo n ¼ 5. *P , 0.05.
L. Ferron et al. 110reversed the effect of aldosterone on cell viability (Figure 6B). Thus,
aldosterone-dependent apoptosis and necrosis are induced by both
ICaT and ICaL.
4. Discussion
We have investigated the signalling pathway(s) of ICaT and its impli-
cation in cardiomyocyte death. In this context, we have focused on
the pathway(s) by which aldosterone upregulates Cav3.1 expression
to generate ICaT and identiﬁed mechanisms involved in cacna1g
expression.
We show here that, in neonatal cardiomyocytes, aldosterone-
induced increase in ICaT density results mostly from an increase in
Cav3.1 expression. The transactivation of cacna1g by GR was
observed with either aldosterone or dexamethasone (1 mM), but
aldosterone-activated GRs targeted a GRE (GRE1) that is different
from those targeted by dexamethasone-activated GRs. The
aldosterone-induced increase in ICaT-generated Ca
2+ signalling led
to molecular remodelling. Indeed, we found that aldosterone-induced
CREB phosphorylation was altered by ICaT-generated Ca
2+ signalling,
likely resulting in a reduced transcription of CREB’s target genes. ICaT-
signalling also exerts a negative feedback regulation on cacna1g
expression, which occurs only after exposure to aldosterone for
9 h, suggesting that functional channels are not present at the mem-
brane before that time. While there is still insufﬁcient evidence to
infer the existence of a direct interaction between CREB and the
GR-binding cacna1g promoter, it seems likely that the ICaT-induced
decrease in cacna1g expression is due to a defect in CREB interfer-
ence with the GR-binding activity of GRE1. Further investigations of
this issue are required.
We also found that the decrease in phosphorylated CREB levels
was mediated by an ICaT-induced increase in PP2A and, to a lesser
extent, to PP1 activities. However, PP2B exerts opposite effects on
CREB phosphorylation because PP2B blockade prevented
aldosterone-induced CREB phosphorylation without affecting the
total amount of CREB, therefore excluding the possibilities of an
increase in ubiquitination and the degradation of phosphorylated
CREB.
22 In the heart, several isoforms of phosphodiesterase (PDE)
hydrolyze cAMP and cGMP,
25 and the activities of these enzymes
are modulated by phosphorylation.
26 Therefore, PP2B blockade may
decrease CREB activation by inhibiting PDE dephosphorylation,
thereby increasing PDE activity. Indeed, the inhibition of PDE4 was
shown to elicit cAMP/protein kinase A-dependent CREB phosphoryl-
ation in cardiac cells.
27 A priori, our results differ from those describ-
ing an inhibitory effect of aldosterone-activated MRs on CREB
phosphorylation through PP2B in vascular smooth muscle cells.
28
However, in cardiomyocytes, the response to aldosterone is mediated
mostly by GRs and our results are thus consistent with the reported
positive effect of dexamethasone-activated GRs on CREB signalling.
28
A cross-talk between ICaT and CREB signalling is consistent with
their opposite expression proﬁles, together with their antagonistic
physiological functions. ICaT and CREB signalling do not seem to be
critical for normal cardiac function
8,29 but, in pathological conditions,
CREB signalling was implicated in angiotensin II-induced hypertro-
phy.
30 Stenosis-induced hypertrophy showed an opposite pattern in
terms of ICaT re-emergence and CREB activation. Indeed, hypertro-
phied cardiomyocytes in the rat 6-week-stenosis model displayed an
increase in phosphorylated CREB levels. The phosphorylation of
CREB was almost abolished in the 12-week stenosis group and
coincided with ICaT re-emergence. In addition, when the
re-emergence of ICaT is reversed, the decrease in ICaT density is cor-
related with a re-increase in phosphorylated CREB protein levels.
Therefore, the negative feedback of ICaT on CREB signalling observed
in neonatal cardiomyocytes also seems to occur in pathological con-
ditions in the adult. This result also suggests that ICaT signalling renders
cardiomyocytes resistant to hypertrophic factor-induced CREB signal-
ling in the later stages of cardiac hypertrophy. Thus, loss of the nega-
tive feedback regulation of CREB signalling by ICaT may partly account
for the hypersensitivity to hypertrophy described for Cav3.1
2/2
mice.
8
The CREB and ICaT-signalling pathways have opposite effects on cell
proliferation. For example, ICaT signalling and CREB signalling have
antagonistic effect on the pathway mediated by cell-cycle inhibitor
p21CIP1.
31 This feature is particularly important in heart, as recent
study has reported the persistence in adolescent heart of immature
cardiomyocytes with ICaT-generated Ca
2+ inﬂux.
32 The CREB and
ICaT-signalling pathways also have opposite effects on cell-death pro-
cesses. CREB signalling was presumed to have anti-apoptotic effects
through the upregulation of Bcl-2
33 and the prevention of
NO-induced apoptosis.
27 Conversely, the activities of PP2A and PP1
have been associated with cell apoptosis.
23 Our study shows that, in
aldosterone-treated cardiomyocytes, ICaT-induced PP2A activation
increases the expression of pro-apoptotic markers, such as caspase
9 and the Bcl-xS variant. Consistent with these ﬁndings, cardiomyo-
cyte apoptosis was ﬁrst detected 24 h after aldosterone exposure
and the longer term (48 h) effects of aldosterone involve an increase
in necrosis rather than apoptosis. The blockade of ICaT-generated
Ca
2+ signalling decreases cell death by reducing both apoptosis and
necrosis, whereas, as previously reported,
34 the blockade of ICaL
decreases necrosis rather than apoptosis. Aldosterone therefore
induces different signalling pathways through Ca
2+ microdomains,
related to either ICaT-o rI CaL-generated Ca
2+ inﬂux, such as the acti-
vation of PP2A–PP1 or PP2B,
24 respectively, resulting in temporally
regulated cell processes. Consistent with this idea, an increase in
the levels of apoptotic markers in the pathological model was associ-
ated with the re-emergence of ICaT in long-term stenosis (Supplemen-
tary material online, Figure S5). Nevertheless, further investigation will
be needed to conﬁrm the relationship between PP2A and CREB
dephosphorylation in adult rat during heart pathology.
In conclusion, the main ﬁnding of our study is that the increase in
ICaT density induces Ca
2+ signalling, which targets PP2A–PP1 and
results in a downregulation of CREB target genes such as those associ-
ated with cardiac hypertrophy. Through its targeting of PP2A–PP1,
ICaT increases pro-apoptotic markers and cell death. Although neo-
natal cardiomyocytes in culture do not completely reﬂect what
takes place in the adult, we conﬁrm that the re-emergence of ICaT
in a long-term cardiac hypertrophy model is associated with the
reduction of CREB-mediated gene expression and the stimulation of
expression of apoptotic markers. Thus, our results suggest that,
during cardiac pathology, ICaT may limit the progression of hypertro-
phy, thereby corroborating the conclusion of Nakayama et al.
8
Whether or not cell death induced by ICaT has a ‘protective’ effect
against heart disease, such as described by Nakayama et al., is difﬁcult
to reconcile and needs to be further investigated. However, it is note-
worthy that the protective effect of ICaT described by Nakayama et al.
occurs via an NOS3-dependent signalling, the product of which was
shown to result in cardiomyocyte apoptosis.
35 The ICaT/PP2A/CREB
signalling pathway, described in this study, may represent an
ICaT activates PP2A and cardiomyocyte death 111alternative to ICaT/NOS3/PKG1 signalling pathway involved in the anti-
hypertrophic effect of ICaT during heart pathology.
5. Limitations
Most papers describing an effect of aldosterone on ionic currents in
cardiomyocyte use a concentration of 1 mM aldosterone, and we
found that 1 mM Aldo was indeed the most potent concentration
for upregulating the promoter of the cacna1g gene. We should
point out that 1 mM aldosterone is approximately two orders of mag-
nitude higher than physiological concentration. However, in vivo, the
impact of paracrine effects, such as those of the renin–angiotensin
II–aldosterone system, which is thought to occur in the heart,
36
cannot be ignored. Such effects may locally increase aldosterone con-
centration and increase the impact of plasma aldosterone
concentration.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
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